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ABSTRACT In part 1, we reported that human (H) platelets, activated with high concentrations (10 uM) of adenosine
diphosphate, aggregate under Brownian diffusion (nonstirred, platelet-rich plasma) with an apparent efficiency of collision
(aB) -4 times and 8 times larger than observed, respectively, for canine (C) and rabbit (R) platelets. Further evaluations of
parallel inhibition of aB and shape change suggested a central role for platelet pseudopods in mediating the long-range
interactions associated with the elevated aB values. We found that >90% of all platelet contacts in the doublets and triplets
formed were via at least one pseudopod. We therefore compared pseudopod number and length per platelet generated by
-30 s post ADP activation in nonstirred PRP from human, canine, and rabbit donors, using phase-contrast, video-enhanced
microscopy of fixed platelets. Theoretical calculations assessing the effects of pseudopod length and number on the collision
frequency enhanced by an increased radius of a collision sphere supported the experimental observations that %3 or 4
pseudopods per human or canine platelet, and f5 or 6 pseudopods per rabbit platelet yield optimal aB values, with the
average pseudopod length: %3:2:1 for H/C/R, paralleling the aB differences. After correcting for effects of pseudopods and
platelet size on platelet diffusion and sedimentation, it still appeared that the small number of long pseudopods formed on
human platelets could largely explain the unusually large aB values. The quantitative discrepancies between theory and
experiment do not appear related to time-dependent refractoriness within the <60 s of observation, but may be related to
biochemical differences in dynamics and surface density of adhesive (sticky sites) present on the pseudopod surface.
INTRODUCTION
For blood flowing through blood vessels, the primary
mode of transport of blood platelets to the vessel wall may
be mediated by effects of red cells on radial displacement
of platelets toward the vessel wall, as demonstrated with
latex spheres of similar size as human platelets (1).
However, other enhancements in platelet diffusion toward
or effective collisions with blood cells or the vessel wall
could arise from contributions of the nonspherical plate-
let, such as from motile pseudopods formed with platelet
activation (2), particularly in low flow regimes associated,
for example, with cardiovascular disease (1). It is widely
recognized that pseudopods can facilitate cell to cell
adhesive contacts by (a) minimizing electrostatic repul-
sions (3) and (b) providing a structural framework for
intercellular membrane spreading for "stabilization" of
adhesive contacts (4). In addition, it has been recognized
that platelet shape change allowing aggregation of plate-
lets in flow requires >1 pseudopod per platelet (5, 6)
without any necessary change in main body shape (7, 8).
However, no direct experimental nor theoretical treat-
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ments have appeared to date on the relation of platelet
pseudopod size, number, and efficiency of aggregation.
The simplest approach to evaluating the magnitude of
platelet diffusion which is in excess of that predicted for
simple, spherical particles is to directly measure the rate
of doublet and small multiplet formation of platelets. We
observed in studies with human, dog, and rabbit platelets
in part 1, applying Smoluchowski's theory, that unusually
rapid aggregation occurs in ADP-activated platelet-rich
plasma (PRP) suspensions stirred for <0.5 s to ensure
efficient mixing of the activator without causing signifi-
cant stir-induced aggregation. The apparent aB values
measured over the first 30-60 s post-ADP addition in
these nonstirred PRP suspensions were <1.0, >1, and >> 1
for rabbit, dog, and human platelets, respectively. This
was suggestive of long-range interactions mediated, for
example, by surface projections or pseudopods operating
to bring platelets together at considerably faster rates
than predicted from diffusion of spherical particles (9).
The nature of the unusually high aB values observed for
human platelets was first assessed by examining the
sensitivity of no-stir vs. stir-associated aggregation to
inhibition by selected inhibitors, which pointed to a
central role for shape change. We then explored the
differences in aB between human, dog, and rabbit plate-
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lets by comparing platelet pseudopod number and size
and the extent of pseudopod-mediated platelet contacts in
the doublets which are primarily formed for 10 ,uM ADP
in nonstirred suspensions for all three species. It was
generally found that increasing pseudopod length paral-
leled the increasing aB values measured at early times
(<60 s) post-ADP addition in nonstirred suspensions,
consistent with theoretical considerations presented here
in detail. A model for the interspecies differences in aB
and for the deviations from theoretical predictions is
presented in terms of the physical and expected biochemi-
cal properties of pseudopod membrane surfaces participat-
ing in platelet aggregate formation.
METHODOLOGY
Preparation of platelet-rich plasma
Human donors were healthy males and females between the ages of 19
and 45 yr, not on any medication, and informed consent was obtained.
Mongrel dogs and New Zealand albino rabbits (males and females)
weighed, respectively, 10-20 kg and 3-5 kg. Blood was collected from
human, rabbit, and canine donors as previously described in part 1. In all
cases, blood was collected directly into 3.8% sodium citrate (1:9 vol/vol
blood), and PRP was prepared and maintained at 370C and pH 7.4 as
described previously (10).
Platelet aggregation kinetics
Platelet microaggregation (PA) was estimated from the percent de-
crease in the number of particles as in part 1 (11).
Unstirred, diffusion-dependent studies were performed using 10 AM
ADP as described in part 1; PRP was mixed with ADP for 0.5 s, and
then incubated for varying times with no stir out to 300 s. Stir-
dependent PA studies were conducted with continuous stirring after
ADP addition and fixation at 3 and 10s (part 1). Time-dependent
refractoriness of platelet aggregation was evaluated as previously
reported (13) by comparing stir-dependent PA values (PA3 and PAIo) as
a function of varying incubation times after the above 0.5 s stir (Table
1). Aggregation was arrested and stabilized by addition of 5 vol of 0.8%
glutaraldehyde (part 1).
Inhibitor studies
Inhibition studies were conducted for human PRP activated with 10 UM
ADP using the combination of acetylsalicylic acid (ASA) and prostaglan-
din El (PGE,). The combination of concentrations blocking stir-
associated secondary aggregation (TA-2), normally associated with the
release reaction (12) was determined with the aggregometry device
measuring light transmission (part 1). Thus, 0.4 ml of PRP was
preincubated with 0.1-1 mM of ASA and 0.1-1.5 gM of PGE, for 1
min, followed by addition of 10 MM ADP to the stirred suspension.
Effects of increasing concentrations of these inhibitors on the above
microaggregation studies were then determined for PA3 and PA1o for
continuously stirred suspensions, and for PA measured over 10-300 s for
diffusion-dependent aggregation, as previously reported (13, 14).
The initial rates of platelet shape change (V,) and of platelet
macroaggregation (V.) detected by changes in light transmission after
addition of the 10 MAM ADP to stirred PRP (0.4 ml) in a Payton
aggregometer were determined as in part 1, with % inhibition then
determined as above (14).
Platelet pseudopod contact,
number, and size in aggregation
A drop of the glutaraldehyde-fixed samples prepared for estimating PA
in nonstirred human, rabbit, or canine PRP for post-ADP addition times
of 0, 10, 60, and 300 s, was transferred into a Vaseline well formed on a
glass slide; covered and sealed with a coverslip (application of a slight
pressure) (2) and viewed on a videomonitor (ITC-Ikegami; Ikegami
Tsushinki, Co., Ltd., Tokyo) using phase contrast microscopy (40 x
objective, 1.25 x Optovar, Universal Research Microscope; Carl Zeiss,
TABLE 1 Refractoriness of human, rabbit, and canine platelets to ADP (10 MM)
Extent of refractoriness for*
Prestir ADP PA3 PA1O
incubation time Human canine Rabbit Human canine Rabbit
(s) %
0
10 2 ± 2t 27 0 2 6 0 0
20 8 ± 7 40 0 2 3 0 1±1
30 21 ±20 37 0 6±5 0.5 1 2
60 33 ± 20 31 39 ± 52 22 13 0 18 12
120 - 65 ± 46 38 5
300 42 ± 15 43 98 ±4 34 + 11 0 65 20
PA@Otime 52 ± 16 (8)§ 67 (2)" 18 ± 3 (3) 75 6 (7) 74.5 (2) 66 5 (3)
(no prestir) (24-73) (66-68) (14-20) (63-81) (74-75) (61-71)
*Corrected for no stir PA contributions.
tMean ± SD.
§Number of donors evaluated shown in brackets.
"These two animals were distinct from those studied for Tables 2 and 3.
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Inc., New York) and a solid-state camera (Panasonic WVCD5 1;
Montreal Video, Montreal, Canada).
Platelet contacts viewed in rotating doublets were classified as either
(a) pseudopod to pseudopod contact or platelet main body surface to
pseudopod contact and identified as those doublets which were capable
of moving independently of each other (see Fig. 1); or (b) platelet main
body to main body contact and differentiated as those doublets that
rotated as a single entity. The platelet pseudopod number (N) and
length (Q) were measured from pseudopods protruding from unaggre-
gated platelet surfaces, as each platelet was viewed freely rotating. 20
platelets were randomly selected for determining N per platelet, with
one pseudopod randomly selected from each platelet for measurement of
2. The length of the pseudopods was measured on the screen using a
cursor that is part of the Image Analyzer 2 program (Coreco, Inc.,
Montreal, Canada) installed in an IBM Personal Computer. The
base-to-tip length was measured in pixels, with 9.3 pixels = 1 Mm,
calibrated with a micrometer scale. Reproducibility of lengths was ± 3
pixels = 0.32 Mum. No diffraction rings were discernible on the
pseudopods in contrast to rings previously reported for the main platelet
body (15).
MATERIALS
Trisodium citrate (J. T. Baker Chemical Co., Phillipsburg, NJ) and
ADP (Sigma Chemical Co., St. Louis, MO) were prepared as previously
described (10). Hematall isotonic diluent, azide free (Fisher Scientific
Co., Montreal, Canada), was used for diluting samples for counting.
Glutaraldehyde was freshly prepared in plain Tyrode's (pH 7.4) from an
FIGURE 1 Two human platelets in a doublet linked via pseudopods
each containing further numbers of extended pseudopods. Phase con-
trast micrograph of glutaraldehyde-fixed platelets after 30 s post ADP
(10 MM) (no stir) using the phase-contrast microscope (40 x objective).
The photograph was taken of a scene on the videomonitor (see
Methods).
8% solution (EM arade; Polysciences, Inc., Warington, PA). ASA
(Sigma Chemical Co.) was freshly dissolved in DMSO to make a
30-mM stock solution. PGE, (Sigma Chemical Co.), stored as a solid at
-200C, was freshly dissolved in plain Tyrode's buffer, pH = 7.4, to
make a 98-MM stock solution. Final DMSO vehicle addition to PRP was
< 1.0% vol/vol.
RESULTS
Relative inhibition of ADP-induced
shape change and of stir- and
nonstir-associated human platelet
aggregation
In part 1, we reported that aB values >1 for human
platelet aggregation in nonstirred suspensions were ob-
served only with high ADP and calcium ionophore A23 187
concentrations. These concentrations are normally associ-
ated in stirred platelet suspensions with secondary aggre-
gation and both a and dense granule release (12).
Combinations of ASA and PGE, which inhibited ADP-
induced shape change (SC) and aggregation were there-
fore evaluated, as these have been reported to optimally
block even the partial granule secretion occurring with
blood collection (16). The combination of ASA (100-
1,000 M) and PGE1 (0.1-1.5 1,M) was found to abolish
stir-associated secondary aggregation, with associated
release expected to be blocked (12), while causing major
inhibition of stir-associated rate of macroaggregation
( VA) and variable inhibition of stir-associated microaggre-
gation rate (PA3) and extent (PA1o), as well as of rate of
shape change (V,), shown for three human donors in
Table 2. Major inhibition of nonstir-associated aggrega-
tion, i.e., major reduction in aB values, was observed for
TABLE 2 Differential Inhibition of ADP-induced no-stir
vs. stir-associated aggregation*
Stir No stir
Inhibitor % inhibition % inhibition
Donor ASA PGE1 Vb* PA3 PA1o Vs aB§ PAIO-60 PA300
AM
1 alOO 1.5 69 6 15 0 1.6 6±2 -
b 1,000 1.5 78 24 17 45 85 15 -
2 100 0.1 -1 51 13 - 2.9 12 12 24
3** 1,000 1.0 84 70 43 73 4.1 54 ± 10 81
* 10 MM ADP was used as activator in all cases.
tNote that in all cases secondary aggregation (TA2) has been effectively
blocked.
5Values determined for 0-60 s without inhibitors for 10 AM ADP and no
stir.
"Not determined (-).
**[ADP],/2 for PA (<30 s) no stir and PA3 stir was, respectively,
4.0 ± 0.3 and 1.0MM.
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experimental conditions, where in addition to the inhibi-
tion of stir-associated secondary aggregation (TA-2) and
of rates of macroaggregation (VA), major inhibition
(45-73%) in rates of shape change was also observed.
These experiments suggest that (a) platelet release is
likely not associated with the observed aB values, and (b)
that shape change may play a major role in the kinetics of
no stir-associated aggregation and the observed high aB
values.
Nature of pseudopods and platelet
contacts In no stir-associated
platelet aggregation
As reported in part 1 for human, dog, and rabbit platelets,
.85% of all platelet aggregates formed with 10 ,M ADP
in nonstirred PRP were doublets, with the balance as
triplets. Platelet to platelet contacts observed by direct
microscopy were seen to consist essentially of pseudopod-
pseudopod or pseudopod-main-body contacts (85-95% of
all contacts), with <10-15% consisting of main-body to
main-body contacts (Fig. 1). In light of such a major role
for pseudopods, also suggested by the above inhibition
studies, it was of interest to compare the number and
length of pseudopods per platelet for human, canine, and
rabbit platelets. It is seen from Table 3 that there are on
average -3-4 pseudopods per human or canine platelet
and -5-6 pseudopods per rabbit platelet at '30 s after
addition of 10 ,M ADP. For human platelets, -70% of
these activated platelets are advanced discoechinocytes,
i.e., discocytic with pseudopods, with the balance as
spheroechinocytes (7); however, it is expected that disco-
echinocytes will be initially recruited as previously re-
ported for stir-associated aggregation (8). It was unexpect-
edly observed that the average length of pseudopods on
these ADP-activated platelets was -3 times and 2 times
greater, respectively, for human and canine platelets than
for rabbit platelets (Table 3).
Theory relating platelet aggregation
in nonstirred suspensions to platelet
size and shape
Smoluchowski's theory of coagulation
The aggregation of activated blood platelets is compli-
cated by the fact that the platelets have a complex shape.
When activated, the plate-like shape of platelets is changed
into a less oblate shape from which several pseudopods are
protruding. The length of the pseudopods can vary from a
fraction of the platelet size to a length well exceeding the
platelet length.
The problem of aggregation of spherical particles was
considered first by Smoluchowski (17), who neglected in
his theory the presence of colloidal interaction forces
between the particles and the change in hydrodynamic
resistance when the spheres approach. His theory works
well when the only colloidal forces are attractive van der
Waals dispersion forces, which approximately cancel the
increased hydrodynamic drag. Smoluchowski's result for
the rate at which spheres collide with a reference sphere in
the fluid is
8 kT
JSM= 16irnDa = -n-3 ,U (1)
Here JSM is the number of spheres colliding with the
reference sphere per second, n is the number of spheres
per unit volume, D is the diffusion constant of a sphere, a
its radius, k is the Boltzmann constant, T the absolute
temperature, and u the viscosity of the medium. The last
equality in Eq. 1 is derived from the Stokes-Einstein
relation
TABLE 3 Pseudopods on activated human, canine,
and rabbit platelets: number per platelet and length
Pseudopod
Number per platelet* Length1
N R(Om)
Human 3.5 ± 0.8 (2-5)t 3.2 ± 0.8 (1.7-5.6)
Canine 4.0 ± 1.7 (2-7) 2.2 ± 0.8 (1.1-4.9)
Rabbit 5.5 ± 1.0 (4-7) 1.3 ± 0.3 (0.9-1.9)
*Measured for 20 singlet platelets in PRP for one donor each at 30 s post
10 AM ADP addition for "nonstirred" platelets, with 31%, 18%, and
12% aggregation, respectively, for H, C, and R donors.
tMean ± SD, with range of values shown in brackets.
1There is a highly significant difference between any combination of the
two species: p < 0.001; 29 pseudopods per species analyzed.
Df= kT, (2)
f being the friction coefficient which for a sphere equals
6 ir,Aa.
Often the rate JsM predicted by Smoluchowski is taken
as a reference rate and the actual rate is expressed as
J = aB3mJsm, (3)
where aBM is the collision efficiency for Brownian motion-
induced aggregation. Because JsM is a somewhat arbi-
trary reference flux, aBM can take on any value between 0
and 00. For colloidal spheres subjected to electrostatic and
van der Waals forces, a]BM can be calculated theoretically
(9).
Because Eq. 1 predicts that JsM is independent of
particle size or shape, one might think that it could also be
applied to particles of more complex shapes, such as, e.g.,
31 B.pyia Jora.oue5 uut19312 Biophysical Journal Volume 58 August 1990
blood platelets. However, in Eq. 1, the product Da (which
for spheres is independent of a) arises from Fick's first law
of diffusion:
JSM = 4IrR2D(dn/dr)R, (4)
where R is the radius of the collision sphere (of radius 2a)
and (dn/dr)R = 2N0/R, N. being the concentration of
platelets in the bulk. For activated platelets both R and D
are different from the values for spheres and the product
will no longer be independent of size and shape. To
investigate this in more detail, we need estimates of the
diffusion constant of platelets and the radius of their
collision cross-sections.
Diffusion constant of activated platelets
The shape of an activated platelet can be thought of as an
oblate spheroid from which several spikes are protruding.
As a first approximation we will consider the activated
platelet to be a sphere of radius a, from which N
cylindrical spikes (pseudopods) are protruding of length Q
and cross-sectional radius (of the spikes) s. The diffusion
constant of such an object can be estimated by comparing
it with a composite sphere, consisting of a solid sphere
surrounded by a porous shell. Measurements of friction
coefficient of hairy spheres are found to be in excellent
agreement with this model (18). The results are expressed
in the parameters a and 13, where a = a/k and = b/k, a
being the radius of the solid nucleus and b of the
composite sphere (b = a + Q), k is the permeability of the
shell, related to its volume fraction c by
by -40%. It should be noted that in the absence of
pseudopods the diffusion constant of a nonactivated
platelet is smaller than that of an equivalent sphere
(because of its nonspherical shape), but this will little
affect the ratio D/D,
Radius of collision sphere of activated
platelets
For activated platelets, the concept of a collision sphere
becomes ill-defined because two platelets can be either in
contact or not at a given distance, depending on whether
or not the pseudopods make contact or simply interdigi-
tate. Schematically the approach of two platelets is shown
in Fig. 2.
If one assumes that two platelets come into effective
contact when a pseudopod of an approaching platelet
penetrates a distance d in the "porous shell" layer of the
reference platelet, then the radius of the collision cross-
section equals
R = 2a + 2R - d. (7)
An estimate of d can be made by considering both the
rotational and translational motion of the platelets and
assuming that two platelets aggregate when two pseudo-
pods make contact. Suppose a pseudopod has penetrated a
distance d into the influence sphere of a reference platelet.
What is the probability that the pseudopod makes contact
with a pseudopod of the reference platelet before it
diffuses out of the influence sphere? On average it takes a
time
ttrans- d2/2Ds2 - _C2
k = --Inc +
I+C (5)
The theory (18) provides a somewhat complex relation
f(a, 13) between the friction coefficientf of the composite






to diffuse out of the influence sphere of the reference
platelet. During that time the reference platelet is rotat-
ing due to rotary Brownian motion and, if the particle
rotates sufficiently, one of its pseudopods will make
contact with one of the pseudopods of the approaching
platelet before it can translate away. On average, the
(6)
Hence, from the values of a, Q, s, and N, we can determine
c and k and thus a and a and subsequently from the
relationf(a, 13) we can obtainf. The diffusion constant D
then follows from Eq. 2. E.g., assuming a = 1.2 ,um, Q =
3.2 ,um, s = 0.1 ,um, and N = 4 yields c = 1.15 * 10-,
k = 6.3 UMm2, a = 0.48, d = 1.76 andf= 0.45fb,fb being
the friction coefficient of a solid sphere of radius b. It
follows from Eq. 2 that D (a/0.45b)DO = 0.6 D., D.
being the diffusion constant of the sphere without the
spikes (of radius a). It follows that in this case the
presence of pseudopods decreases the diffusion constant
FIGURE 2 Schematics of two activated platelets approaching each
other (N = 3).
Frojmovic et al Pseudopod Role in Platelet Aggregation 313Frojmovic et al. Pseudopod Role in Platelet Aggregation 313
angle between a pseudopod of the reference platelet and
the projection of the nearest pseudopod of the approach-
ing platelet will be X w7r/N (see Fig. 2). An estimate of d
can be made by equating ttrans with trot, with trot given by
trot = &2/2D, (9)
Collision efficiency of activated platelets
From the ratio DIDO, and Eqs. 3 and 11, it follows that
the collision efficiency for Brownian motion induced
coagulation of activated platelets equals:
Dr being the rotary diffusion constant, which for spheres




By combining Eqs. 7 and 10 it can be seen that the radius
of the collision cross-section can be approximated as
R Q 2w
2a a 3N (11)
So far we have assumed that the platelets were spheri-
cal. Approximating their shape by an oblate spheroid of
axis ratio rp = a2/a1 (rp < 1), it follows from Eq. 4 that R
must be replaced by
R c- 2ala2 (TFr)R.
However, because
2 1(2 2 \ 1 a+ a2\
r 22a + 2a2 2 ( a, * a2'
we conclude that R t a, + a2 t 2aeff, aeff being the
equivalent radius of the spheroid. It follows that Eq. 11 is
also valid for spheroidal particles, provided a t
1/2 (a1 + a2). This condition is satisfied for the different
mammalian unactivated discocytes (Table 4) as well as
for spheres (a, = a2) and intermediate activated forms
(6,7).
TABLE 4 Size and shape of platelets
Nonactivated platelets
Effective
Length Width Volume radiusi
(CM) (#M) (JM3) (JM)
Human* 3.6 0.9 4-8 1.2
Caninet 3.6 0.9 4-8 1.2
Rabbit* 3.2 0.6 1-6 0.9
*Data previously reported for two human and four rabbit donors (15).
tData set to that for human platelets as mean electronic volumes have
been reported as identical (21) and our analysis of one dog's PRP gave
similar results: length 4.3 Am, width 0.9 Am, calculated volume 9 gm3,
and effective radius 1.29 MM.
Determined for the volume of an equivalent sphere.
(12)
The various terms in Eq. (12) all have a well-defined
physical meaning. The term D/Do lowers the efficiency
because of the decrease in Brownian motion. The first
term in brackets is the efficiency of platelets without
pseudopods, the second term increases the efficiency
because of the presence of pseudopods, and the last term
reduces it because pseudopods can diffuse out of the
influence sphere of neighboring platelets before being
captured. Because the relation -7,/N is only expected
to hold for a sufficient number of pseudopods, Eq. 12 can
be expected to hold when N> 2.
Predictions of collision efficiencies as a function of the
number of pseudopods are shown in Fig. 3.
It can be seen that for human platelets the efficiency is
maximum (-200%) when N = 3 or 4. The decrease for
large N is due to the fact that for a large number of
pseudopods the particle starts to behave as a solid sphere
of radius band thus aBM -O asN oom. It follows that the
formation of more than four pseudopods per platelet has
no advantage in promoting aggregation. The reason is
that the decrease in D/Do becomes more important than
the increase in R. For canine and rabbit platelets, the
maximum occurs near four and six pseudopods, respec-
tively, and the maximum is much less pronounced.
Effects of sedimentation of platelets
Because not all platelets have exactly the same size and
density, platelets will sediment with various sedimenta-
tion velocities. The difference in velocity can cause
platelets to collide resulting in aggregation.
The number of particles sedimenting with velocity u2
colliding with a reference particle sedimenting with
N
FIGURE 3 Predicted collision efficiencies as a function of the number of
pseudopods for activated platelets. Human: a = 1.2 Mm, 2 = 3.2 gm,
s = 0.1 Mm; Canine: a = 1.2 gm, Q = 2.2 um, s = 0.1 Mm; Rabbit: a,=
0.9 um, Q = 1.3 um, s = 0.1 m (taken from Tables 3 and 4).
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velocity ul equals
J,.d = nAuirR2 (13)
where n is the number of particles with velocity U2, AU =
U2- u and R is the radius of the collision cross-section,
given by Eq. 7, but with d estimated as
Auir2 4ir3,uaAu
2N2Dr N2kT (14)
Each particle settles with a velocity determined by
mg = fu, (15)
where g is the gravitational acceleration constant and m
and f the mass and friction coefficients of the platelet.
Hence
Au
=g[(3ra2 + N2 12
-(4ira3 + N,7rslIi) API] (16)
The subscripts 1 and 2 refer to the reference and
approaching platelet, respectively. Ap is the density differ-
ence between particle and fluid. The ratio of aggregation
rates due to sedimentation and Brownian motion equals
J..d RAu 6iruaa2Au
JBM 8D kT (17)
For human platelets, taking a2 = 1.3 gm, a, = 1.1 m,
AP2 30 kg/m3, and Ap, 10 kg/mi3, results in values ofAu of
-50 nm/s, and values of a in the range 0.1-0.3. It follows
that aggregation due to sedimentation is less important
than aggregation due to Brownian motion. When Brown-
ian motion and sedimentation are both present, the
coagulation rate is, when a << 1, given (19), by
J = JBM(1 + aBMa) (18)
It follows, if one defines an effective collision efficiency aeff
by J =aeffJsM, that
a,ff = aBM(1 + aBMa). (19)
Comparison between theory and
experiments
An approximately inverse relationship was observed be-
tween the number of pseudopods per activated platelet
(N) and the average length of pseudopods (R) for human,
canine, and rabbit platelets, i.e., rabbit platelets have the
largest number of much shorter pseudopods per platelet
than seen for canine or human activated platelets (Table
3). Average pseudopod lengths (Q) and equivalent sphere
radii (Table 4) were used in calculating the collision
efficiencies for Brownian motion, aBM, for platelets from
these three species (Fig. 3), as a function of N. These
predicted aBM values were found to have maximal values
for N in the range actually observed experimentally
(compare Fig. 3 and Table 3).
Using the average values of N and 1 in Table 1, we
calculated the average values of the relative contributions
of sedimentation to Brownian motion (a), and the resul-
tant effective collision efficiency (a,eff). These are pre-
sented in Table 5 and compared with experimentally
observed values (a.,p) derived from the data presented in
part 1.
It can be seen that the predictions and experiments
agree within one standard deviation, although for rabbit
platelets the mean experimental value is -55% of the
theoretical one. For human platelets the error in the
experiments is rather large, possibly reflecting the diffi-
culty in measuring initial aggregation rates. The theory
applies to two platelet interactions only, not to the
subsequent growth of aggregates. Table 5 shows that the
decrease in diffusion constant (due to the presence of
pseudopods) is more than offset by the increase in the
radius of the collision cross-section.
DISCUSSION
In part 1, we found that the apparent efficiency of
Brownian diffusion controlled aggregation (aB) of plate-
lets activated with high ADP concentrations varied as
-8:2:1 for human >> canine > rabbit platelets. We
initially compared human and rabbit platelets, whose
mean size differ by twofold (15), and then included canine
platelets which are of identical size as human platelets
(20) but which showed aB values more comparable to that
seen for rabbit platelets. Thus, aB did not appear to
depend on platelet volume. The most likely model for
these large aB values observed in part 1 appeared to be
one based on long-range interactions associated with
pseudopod production distinct for each of these species.
TABLE 5 Comparison between predicted and
observed collision efficiencies
D/DO R/2a aBM a aCff* a,xpt
Human 0.60 3.3 2.0 0.3 3.2 ± 0.7 8 ± 5
Canine 0.65 2.3 1.5 0.3 2.2 ± 0.6 2.1 ± 0.7
Rabbit 0.67 2.1 1.4 0.1 1.6 ± 0.3 0.9 ± 0.4
*Errors estimated from variations in number and length of pseudopods
and uncertainty in pseudopod thickness. Other entries are average
values. aeff calculated from Eq. 19.
$aeXp = aB values reported in part 1.
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This was consistent with our observations in this report
that a major reduction of aB values for ADP-activated
human platelets was only observed at concentrations of
inhibitors causing parallel major inhibition of platelet
shape change (ASA/PGE, in Table 2).
We examined experimentally and theoretically the
relationship between platelet pseudopod number and size
vs. aB values obtained for human, rabbit, and canine
platelets. We found surprisingly good correlations be-
tween our theoretical predictions and experimental obser-
vations. Thus, the average maximal number of pseudo-
pods per platelet (N) present -30 s after platelet activation
with 10 ,M ADP appears characteristic for each species
evaluated, with only three to six pseudopods per platelet
required to yield maximal predicted collision efficiencies
(aBM in Fig. 2), with greaterN actually predicted to lower
aBM. The predicted optimal values ofN 3-4 for human
and canine platelets, and -6 for rabbit platelets, were
experimentally observed (Table 3). These results are
consistent with our observations that .85% of all platelet
contacts in doublets or triplets formed in diffusion-
controlled aggregation for all three species were via one or
more pseudopods, directly visualized by microscopy. Such
a central role for pseudopods as an absolute prerequisite
for platelet to platelet contacts has been previously
reported for continuously stirred platelet suspensions for
ADP or adrenaline as activator, where >1-2 pseudopods
per platelet on the surface even in the absence of main
body shape change, appeared necessary for microaggrega-
tion (5, 8). Thus, 10 ,uM ADP-activated human PRP
showed >85% of all doublets joined by at least one
pseudopod whether -30% of all platelets formed doublets
by -20-30 s of no stir or by -2 s of continuous stir.
In stirred suspensions, rapid rotation of platelets abol-
ishes the advantages conferred by the distinct platelet
number and length of pseudopods on human platelets vs.
canine or rabbit platelets, as no differences in continu-
ously stir-associated rates of microaggregation were ob-
served for these three species (part 1). However, the effect
of pseudopods on the radius of the collision cross-section
ofhuman platelets in Brownian diffusion-associated aggre-
gation vs. canine and rabbit platelets has been predicted
to yield relative aB values, corrected for differences in
diffusion and sedimentation, of the order of 4:2:1 (see a,ff
in Table 5). In particular, however, aCeff predicted for
human platelets appears up to -50% smaller than experi-
mentally observed. This could arise from an underestima-
tion of effective pseudopod lengths (Q) associated with our
studies of glutaraldehyde-fixed cells, because it has been
reported that human platelet pseudopods can dynamically
extend and retract by up to 50% of their time-averaged
length (2). Possible error in pseudopod length, Q, due to
our measurement of only unaggregated platelets, was
shown to be negligible. We compared Q for human PRP
activated with 10 AuM ADP for 30 s (no stir) at platelet
counts of 335,000 ul-' and diluted to 36,000 1ul-1 respec-
tively, yielding microaggregation of 38 ± 1% and 2 ± 2%.
Mean Q values for the partially aggregated and nonaggre-
gated PRP were identical, respectively, 3.1 ± 0.4Aum and
3.1 ±+0.6,um.
Given the lower aB observed values for rabbit platelets
than theoretically predicted (Table 5), and given the
decrease in aB toward lower and comparable values
(-0.5) for all three species' platelets when analyzing the
aggregation data for nonstirred platelet suspensions over
longer times after ADP addition (part 1), the possible
contribution of time-dependent loss of platelet functional
response to 10 ,uM ADP was evaluated for stirred plate-
lets from all three species (Table 1). As previously
reported for human PRP studied with 2 ,tM ADP (13),
.95% of human platelets remained aggregable when
stirred after <30 s preincubation times with ADP (PAIO
in Table 1), with only minor inhibition of rates of
aggregation (PA3 values in Table 1). This was also
observed for canine and rabbit platelets, suggesting that
refractoriness over the early times of observation (<30 s)
is not a significant factor in explaining the experimental
differences in aB values observed at these early times. In
addition, time-dependent decay in aB at post-ADP times
of >60 s can only partially be explained by the stir-
dependent measurements, with the highly variable results
at times >60 s (Table 1) not reflected in the aB measure-
ments.
Our observations on the apparent dependence of aB on
pseudopod length (Q) for activated platelets from three
different species (Table 5) raise the possibility that the
large decreases in aB seen for human platelets with (a)
increasing postactivation time (Fig. 4 in part 1) or with
(b) decreasing ADP activator concentration (Table 4 in
part 1), may be related to corresponding changes in
pseudopod length (Q). However, the above changes in aB
were not paralleled by any significant changes in as
determined with one human donor's platelets: (a) Q =
2.6 ± 1.0 ,um and 2.8 ± 1.0LOm for 10 M ADP activation
observed at 30 s and 5 min, respectively, and (b) Q =
2.7 ± 1.0 ,um and 3.1 ± 0.9 ,um for 5 ,uM and 1 ,M ADP
activation, respectively, measured at 30 s.
A distinct time-dependent mechanism may exist for
refractoriness of unstirred platelets centered, e.g., on a
time-dependent loss in stickiness of one or more pseudo-
pods, e.g., redistribution of sticky sites toward the pseudo-
pod base or platelet main body. Such a pseudopod-
dependent refractoriness would not be expected to be as
important in stir-associated aggregation where platelet
rotary diffusion is slow compared with very rapid flow-
associated platelet collisions. It is widely accepted that the
sticky sites on activated platelet surfaces which mediate
platelet aggregation usually consist of fibrinogen specifi-
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cally bound to its integrin receptor, glycoprotein lIb-IlIa
(21-23.). The ability of these fibrinogen-occupied mem-
brane surface receptors to move together into surface
clusters is well documented (21, 22). Intrinsic species-
dependent differences in the generation of sticky sites on
activated platelet pseudopods could also explain the
differences in aB observed at early times from values
predicted theoretically (Table 5), e.g., human platelet
pseudopods may have greater numbers of fibrinogen
receptors (sticky sites) per unit area of membrane than do
rabbit platelet pseudopods. This could result in shorter
interpenetration distances required for two rabbit plate-
lets, i.e., shorter, effective radius of collision and corre-
spondingly smaller values of aBM than predicted from
maximal pseudopod lengths. These aspects of sticky
properties of pseudopods is being evaluated with immuno-
cytochemical electron microscopy (21, 22).
The requirement of highADP concentrations for achiev-
ing maximal aB values much in excess of that required for
maximal rates of stir-associated aggregation (part 1) is
also consistent with the need to form maximal numbers of
fibrinogen sticky sites on platelet pseudopods (23). A
minor role is expected for the release of adhesive proteins
such as thrombospondin or new receptors for fibrinogen
(23), because (a) minor release is expected in our
experimental conditions where only doublets and triplets
are formed (6) and (b) aB was not significantly affected
when combinations of inhibitors were used at concentra-
tions blocking stir-associated secondary aggregation/
release (Table 2) (12) and reported to block even the
minor release occurring with blood collection (16). Thus,
neither the endoperoxide pathway, irreversibly blocked by
>100 ,uM ASA (12), nor dense granule release, blocked
by ASA/PGE1 (16), appear necessary for the apparent
long-range interactions associated with the high aB val-
ues.
It is expected that the physical and biochemical proper-
ties of platelet pseudopods may play a major role in
regulating adhesive events with other blood cells and
surfaces occurring in hemostasis and thrombosis in a
variety of flow regimes and clinical conditions. For
example, the effects of increased numbers of circulating
platelets with pseudopods in thromboembolic complica-
tions, as recently reported for patients with coronary and
cerebral artery disease (24), remain to be determined.
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